International Biotechnology (Ordinary Share) IBT

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV


Share Price


Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
International Biotechnology (Ordinary Share) Price 79.52%
International Biotechnology (Ordinary Share) NAV 81.53%
FTSE World 18.73%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement


Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 382.4 -14.8% 449.00 459.00
10 Feb

Discrete performance % over

Fund / BenchmarkMar '13
Feb '14
Mar '14
Feb '15
Mar '15
Feb '16
International Biotechnology (Ordinary Share) Price43.0254.62-18.82
International Biotechnology (Ordinary Share) NAV49.2744.54-15.86
FTSE World11.2416.09-8.06

Discrete performance over

Discrete Performance

Top 10 Holdings

Amgen Inc 7.62%
Celgene Corporation 7.62%
Regeneron Pharmaceuticals, Inc. 7.43%
Gilead Sciences Inc 7.43%
Ophthotech 4.67%
Biogen Idec Inc., 4.48%
Vertex Pharmaceuticals 3.90%
Alexion Pharmaceuticals, Inc. 3.81%
Incyte Corporation 2.95%
Biomarin Pharmaceuticals, Inc. 2.76%

Sectors weighting

Biotechnology 105.00%
Net Current Assets -5.00%

Regional weighting

North America Region 85.00%
Europe Developed ex-UK 10.00%
UK 5.00%
Cash/Cash Equivalent 0.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 31 Mar 1994
  • Currency GBX
  • Domicile UK
  • Share Price 387.25
  • Share Type Ordinary Share
  • ISIN GB0004559349
  • Shares Issued (M) 40
  • Market Capital (£M) 154.66
  • Gross Assets (£M) 178.11
  • Net Assets (£M) 178.11
  • TER (%) 1.65
  • Last AGM 09 Dec 2015
  • Next AGM 09 Dec 2016
  • Last Annual Report Date 06 Nov 2015
  • Next due Report Date 29 Feb 2016
  • Next due Report Type I/R
  • Objective:

  • To achieve capital growth through investing in high growth, development stage biotechnology companies.
  • Management Group(s):

  • SV Life Sciences Managers LLP
  • Managed by:

  • Ailsa Craig Start: 01 Jan 2005
  • Carl Harald Janson Start: 02 Sep 2013
  • Kate Bingham Start: 01 Jan 2005
  • Management Contract & Fees:

    The Manager is entitled to a management fee payable monthly at 0.9% p.a. of the Company's NAV. The Investment Manager is entitled to an annual performance fee calculated as follows: The portfolio consists of two pools: quoted and unquoted. The fee on the quoted pool is 10% of relative outperformance above the pound sterling adjusted NASDAQ Biotech Index (£ NBI) plus a 0.5% hurdle. The fee on the unquoted pool is 20% of net realised gains, taking into account any unrealised losses but not unrealised gains, with a high water mark. The payment of the performance fee is subject to the following limits: - the maximum performance fee in any one year is 3% of average net assets during the year, with any excess held over and adjusted up or down according to the performance of the share price over the period between the end of the period in which it is earned and the period in which it becomes payable, - the performance fee for any period may not cause the NAV of the Company to drop below the NAV on the first day of the relevant period - a fund high water mark, initially set at close of business on 31-Aug-11, will be reset whenever a performance fee is paid. It will also be reset upwards or downwards for share buy backs or fund raisings or any other movement associated with a change of capital. The Management Agreement is terminable by either party on 12 months' notice.